Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available, but did not show desired therapeutic effect in current clinical practice. It is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. To precisely identify the dysregulation of signaling pathways and the "driver" oncogenic biomarkers, as well as to develop reliable and reproducible risk-stratification based on biomarkers will be challenging. Nevertheless, pathway-based targeted therapy will raise the hope to improve the outcomes of the patients with lymphoid malignancies, especially with aggressive types, and the efficient utility of pathway-related biomarkers in diagnosis, prognosis, prediction of lymphoid malignancies may also be able to power precision medicine.
Introduction
Lymphoid malignancies are known for a wide variety of types and molecular and clinical heterogeneity. Increasing evidence supported that many dysregulated oncogenic signaling pathways and aberrant genetic alterations have contributed to the oncogenesis and heterogeneity. 1, 2 The most frequently dysregulated signaling pathways involved in lymphoid malignancies include B-cell receptor (BCR) pathway, nuclear factorkappa B (NF-kB) pathway, phosphoinositide-3-kinase/ v-akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, apoptosis pathway, and programmed death-1/programmed deathligands (PD-1/PD-Ls) pathway.
In the current era of precision medicine, therapeutically targeting dysregulated signaling pathways and their hidden oncogenic biomarkers are becoming hot topics in the field of cancer research and translational medicine worldwide. Meanwhile, progress has been made in risk-stratification of patients based on the targeted biomarkers, accordingly providing optimal intervention for different risk groups. Many preclinical and clinical trials demonstrated that targeted therapies have clinical activity against a broad spectrum of lymphoid malignancies. 3, 4 In this review, to comprehensively understand the detailed mechanisms underlying the development of lymphoid malignancies and the potential of targeted therapy, we summarized several key dysregulated signaling pathways involved in oncogenesis and heterogeneity of lymphoid malignancies. The utility of pathway-related biomarkers for diagnostic, predictive, and therapeutic usage is also included.
BCR signaling pathway
BCR is a transmembrane receptor whose membrane-bound immunoglobulin can bind to extracellular antigen. Correspondingly, immunoglobulinlinked heterodimer of cluster of differentiation (CD) 79A/CD79B can deliver the antigen stimulatory signals from outside to inside the cell. Following a series of molecules activation, BCR signaling and its downstream signaling cascades consequently control precise function of normal B cells. 5 In the three BCR signaling pathways (Fig. 1) , the chronic active BCR signaling pathway is classical and antigen-dependent. With the antigen-mediated BCR clustering towards cell membrane, the cytoplasmic tail of BCR, especially immune receptor tyrosine-based activation motifs (ITAM) domain of CD79A and CD79B, becomes phosphorylated by Src family members. Being subsequently recruited and activated by phosphorylated ITAM, spleen associated tyrosine kinase (SYK) thereby activates downstream signals including PI3K/AKT/mTOR signaling, mitogenactivated protein kinase (MAPK) signaling, NF-kB signaling, and nuclear factor of activated T cells (NF-AT) signaling through phosphorylating bruton tyrosine kinase (BTK) and B-cell linker (BLNK). As linker molecules, AKT and BTK are key components to deliver multiple signals. 2, 6 The tonic BCR signaling pathway and autonomous BCR signaling pathway exist, depending on the interaction between BCR and Lyn/SYK or the two neighboring BCRs rather than external antigenic stimulation. 6 Normal BCR signaling has been proven to be functional in B-cell proliferation, survival, apoptosis, and differentiation; aberrantly activated BCR pathway is related to oncogenesis of several types of B-cell hematologic malignancies, especially in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), active B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), and mucosa associated lymphoid tissue (MALT) lymphoma. 2, 7 Furthermore, several key components in these pathways are potential therapeutic targets or diagnostic biomarkers.
CD79A/B
CD79A, a transmembrane protein with a cytoplasmic ITAM, forms a CD79A/B heterodimer with CD79B, which is required for the BCR aggregation to induce signal-initiating. In about 20% of ABC-DLBCL cases, CD79A and CD79B mutations can be observed, suggesting their oncogenic roles in dysregulation of BCR signaling pathway in specific ABC subtype. 7 
BTK
BTK is fundamental to the function of BCR signaling pathway and its downstream signaling. As a member of Tec family, BTK is by far the most studied cytoplasmic tyrosine kinase. It is restrictedly expressed in B cells and plays an important role in the differentiation and activation of B cells. 8 It is also related to immune function, transcription regulation, and apoptosis modulation due to its function in Toll-like receptor (TLR) pathway and cytokine receptor signaling pathway. 9 In BCR signaling pathway, BTK is responsible for receiving signals from SYK and transducing signals to initiate downstream signaling pathway. 10 Given the key function of BTK in BCR pathway and downstream NF-kB pathway, an inhibitor against BTK, ibrutinib, showed encouraging efficacy on patients with untreated and relapsed/refractory CLL, ABC-DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL). The inhibition against BTK induces downstream kinase inactivation and cell apoptosis through binding to BTK at the C481 residue irreversibly. 11, 12 NF-kB pathway NF-kB pathway is one of the most common signaling pathways (Fig. 1) . In the classical NF-kB pathway that is downstream of BCR and some other pathways, caspase recruitment domain family, member 11/mucosa-associated lymphoid tissue lymphoma translocation protein 1/B-cell leukemia/lymphoma 10 (CARD11/MALT1/BCL10) complex is specific for IkB kinase (IKK) phosphorylation which directly activates IkBa. Subsequently, following activation by active IkBa, RelA/p50 heterodimers translocate into nucleus, executing many functions such as cell survival/anti-apoptosis, proliferation, inflammation, and innate immunity (Fig. 1) . 13e15 In the alternative NF-kB pathway, preferentially, the extracellular initiator is B-cell activating factor receptor (BAFF-R), and the activator of IKK complex that includes two IKKa is NF-kB-inducing kinase (NIK). Additionally, the heterodimer RelB/p50 and RelB/p52 are the major types of dimer. The final effector function of alternative NF-kB pathway mainly involves in lymphoid organogenesis, adaptive immunity, antiinflammatory properties, and B cell maturation. 15, 16 These two NF-kB signaling pathways can be seen constitutively activated in almost all types of lymphoma. In ABC-DLBCL, MALT, Hodgkin's lymphoma (HL), Burkitt lymphoma (BL), and some other lymphomas, constitutively activated NF-kB signaling pathway may mostly or partly result in the oncogenic Fig. 1 . Illustration of cross-communication network of BCR, PI3K, apoptosis, and NF-kB signaling pathways. BCR, PI3K/AKT/mTOR, apoptosis, and NF-kB signaling pathways are independent but interconnected and may form complex crosstalk network. One pathway may act as upstream or downstream of other pathways and some molecular targets function as key points and players involved in several pathways. These key molecules have been shown promise to be a good therapeutic target for effective treatment in lymphoid malignancies. The green arrows indicate direction of activating signaling steps; the red bars indicate inhibitory signaling steps. AKT: v-akt murine thymoma viral oncogene homolog; ARF: alternative reading frame; AP-1: activator protein-1; BAFF-R: B-cell activating factor receptor; BAX: BCL2-associated X protein; BCL: Bcell leukemia/lymphoma; BCR: B-cell receptor; BID: BH3 interacting death agonist; BTK: Bruton's tyrosine kinase; CARD11: caspase recruitment domain family, member 11; CD: cluster of differentiation; EBV: EpsteineBarr virus; FADD: Fas associated via death domain; FasL: Fas ligand; IKK: IkB kinase; IkB: inhibitor of nuclear factor kB; MALT1: mucosa-associated lymphoid tissue lymphoma translocation protein 1; MAPK: mitogen-activated protein kinase; MAPKK: mitogen-activated protein kinase kinase; MAPKKK: mitogen-activated protein kinase kinase kinase; MDM2: mouse double minute-2 homolog; mTOR: mechanistic target of rapamycin; MYD88: myeloid differentiation primary response 88; NEMO: NF-kB essential modifier; NFAT: nuclear factor of activated T-cells; NF-kB: nuclear factor kappa B; NIK: NF-kB-inducing kinase; PI3K: phosphoinositide-3-kinase; PTEN: phosphatase and tensin homolog; STAT: signal transducer and activator of transcription; SYK: spleen associated tyrosine kinase; tBID: truncated BID; TCR: T-cell receptor; TLR: Toll-like receptor; TNF: tumor necrosis factor; TNFR1: tumor necrosis factor receptor 1; TRADD: TNFRSF1A associated via death domain.
events, mediated by specific mutation of CARD11, CD79A/B, and myeloid differentiation primary response 88 (MYD88), or chromosomal translocations and EpsteineBarr virus (EBV) infections. 7,17e19 The integrated mediators of NF-kB signaling cascades include MYD88, p50, p52, c-Rel, CD30, and CD40, etc.
MYD88
MYD88 participates in the activation of both NF-kB and JAK/STAT signaling pathways through TLR/ interleukin-1 (IL-1) mediation. 20 MYD88 L265P mutations have not only been identified as the hallmark of CLL and LPL/Waldenstrom's macroglobulinemia (WM), but also have been found to be related to poor outcome of a subset of DLBCL patients. 19 Therefore, it is reasonable to believe that patients with MYD88 L265P mutations and dysregulated NF-kB pathways may benefit from drugs inhibiting interleukin-1 receptor associated kinase 4 (IRAK4) that is downstream of MYD88 and is closely related to the function of MYD88, or interrupting NF-kB pathway, TLR/IL-1 pathway, and other related pathways.
20,21

CD30
CD30, a transmembrane cell-surface member of the tumor necrosis factor receptor superfamily, is one of the activators of the NF-kB pathway, and is highly restrictedly expressed in tumor cells in classical HL (cHL), anaplastic large cell lymphoma (ALCL), and a subset of DLBCL and EBV-driven lymphoproliferative disorders. 22 In clinical practice, CD30 was mainly used as a valuable diagnostic biomarker to diagnose cHL and ALCL. It was also showed in a study that soluble CD30 in serum could predict poor outcomes and disease progression in CD30-positive lymphomas. Apart from as a diagnostic and predictive biomarker, CD30 has been utilized as a target to develop inhibitor agents, typically like brentuximab vedotin, to treat lymphomas with CD30 high expression, such as HL and ALCL. 
PI3K-AKT signaling pathway
Following several upstream pathways like BCR pathway, the PI3K-AKT pathway is an important intracellular signaling pathway in regulating cell cycle and is directly related to cellular quiescence, proliferation, cancer, and longevity. 23 PI3K receives upstream signals and then actives AKT via phosphatidylinositol-3,4,5-triphosphate (PIP3). As an oncogenic factor, activated AKT can target many molecules, indirectly activating mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) and increasing mRNA translation, protein synthesis, and cellular proliferation as a result.
23e25 During this PI3K-AKT signaling process, phosphatase and tensin homolog (PTEN) acts as a negative regulator (Fig. 1) . 26 Considering the oncogenicity conferred by PI3K/ AKT/mTOR pathway in several types of lymphomas, the main drivers have been explored in numerous studies. The oncogenic activation may be driven by PIK3CD mutation and copy number increase of PIK3CA in DLBCL and MCL, respectively. In germinal center B-cell-like (GCB)-DLBCL, loss of function of PTEN may be the main driven cause. 
PI3Ks
PI3K family includes three classes of kinase on the basis of their different structures and functions. Isoforms p110a, p110b, p110d, and p110g belong to Class I and are more frequently related to cancer. Among them, p110d and p110g are related closely to B-cell, T-cell, and natural killer (NK) cell development, proliferation, cytokine secretion, and other cellular functions. 30, 31 Therapeutically, as a representative inhibitor of p110d isoform, idelalisib has exhibited clinical activity in relapsed CLL, MCL, FL, and DLBCL. In addition to its direct inhibitory effect on p110d, the efficacy of idelalisib may also be due to the indirect regulation of cytokines and chemokines secretion in the microenvironment. 31e33 Other inhibitors, such as buparlisib against pan class-I PI3K and duvelisib against p110d/ p110g isoform, also have showed efficacy in both T-and B-cell lymphomas. 34, 35 AKT and PTEN AKT and PTEN act as positive and negative mediator of downstream PI3K pathway, respectively, regulating biological processes like cell survival, growth, proliferation, and angiogenesis. 36 Owing to some alterations at genetic and epigenetic level, as well as proteineprotein interaction, loss-of-function of tumor suppressor PTEN protein may cause the increase of AKT and mTOR activity, which promotes tumor growth and other pathological changes. 37, 38 GCB-DLBCL and MCL are the major lymphoma types involved in functional deficiency of PTEN. 39, 40 Since the inactivation of PTEN is closely associated with the abnormal activation of PI3K/AKT/mTOR pathway, therapeutically targeting PI3K/AKT/mTOR pathway to treat malignancies with PTEN deficiency may be rational. 37, 38, 41 For instance, MK-2206 as a second-generation AKT inhibitor has been used in patients with relapsed/refractory lymphoma in clinical trials. 42 Pan-PI3K inhibitor like buparlisib, p110d-specific PI3K inhibitor like idelalisib, mTOR inhibitor like everolimus, are all in clinical evaluation. 33, 43, 44 Additionally, the immunohistochemical expression of phosphorylated-AKT protein can be used to assess outcome or treatment response in some lymphoid malignancies. 39 mTOR Serine/threonine-protein kinase mTOR is a key protein kinase in the PI3K/AKT/mTOR signaling pathway which is closely related to cellular metabolism, survival, and growth through targeting several types of proteins. mTOR is the structural unit for the function of mTORC1 and mTORC2. After receiving phosphorylation signals from upstream AKT, activated mTORC1 and mTORC2 execute their corresponding function, positively regulating mRNA translation, cell survival, cytoskeleton organization, and negatively regulating autophagy, respectively. 23, 24 Several mTORC1 inhibitors have shown preclinical or clinical efficacy in DLBCL, HL, MCL, FL, CLL/ SLL, and even T-cell lymphomas. Temsirolimus and everolimus are the typical mTORC1 inhibitors. They are also expected to have good efficacy with minimized toxicity, either alone or in combination with rituximab. 43, 45, 46 Apoptosis signaling pathway Apoptosis is a genetically programmed process of cell death and is essential for organism development and environmental homeostasis, which involves many complex molecular mechanisms. There are at least two distinct but interconnected pathways in the process of apoptosis: extrinsic and intrinsic apoptosis pathways (Fig. 1) .
Extrinsic apoptotic pathway is initiated when ligands bind to a specific subset of death receptors, such as Fas and tumor necrosis factor receptor 1 (TNFR1). Fas firstly binds to Fas associated via death domain (FADD) and subsequently unites with caspase 8 to form a death inducing signaling complex, promoting apoptosis downstream caspase 3 and caspase 7 directly, or activating caspase cascades via mitochondrialdependent pathway. 47, 48 Compared with Fas-mediated way, apoptosis mediated by TNFR1 more likely integrates complex TNFRSF1A associated via death domain (TRADD) (death domain-containing proteins like TRADD) and TNF receptor associated factor 2 (TRAF2), inducing cell death or activating NF-kB function through IKK recruitment. 49, 50 In the intrinsic apoptosis pathway, apoptosis is triggered immediately more frequently owing to oncogenic stress, DNA damage and hypoxia. The signals in this pathway are transduced and controlled through interacting with p53, DNA checkpoint proteins, and BCL2 family members located in their upstream or downstream pathways, thereby finally activating caspase 3 and caspase 7 to produce effects like extrinsic pathway. 47, 51 While normal apoptosis pathway is disturbed by multiple cellular and extracellular factors, abnormal proliferation finally results in the oncogenesis of hematologic malignancies. Meaningfully, it is worth exploring the diagnostic, predictive, and therapeutic values of BCL2, Myc, p53 and other molecules involved in apoptosis pathways.
BCL2
BCL2 is one of the members of BCL2 family that programmatically control cell death through antiapoptotic and pro-apoptotic function. BCL2 suppresses apoptotic death in combination with caspases and other BCL2 family members. 52, 53 Owing to its translocation with juxtaposed immunoglobulin heavy locus (IgH), t(14; 18)/IgH/BCL2 is a molecular hallmark of FL and can be also detected in some GCB-DLBCL. 54, 55 By contrast, in ABC-DLBCL subtype, BCL2 is more often amplified. Apart from its diagnostic value in lymphoma, both translocation and overexpression of BCL2 can be used to predict aggressive clinical features and adverse outcome in some types of lymphoma. 40, 56 As for the therapeutic implication, BCL2 appears suitable to develop its inhibitors based on the special structure of BCL2 homology domain 3 (BH3) that can be mimicked through binding to BCL2 or BCL-XL. 57 Obatoclax and venetoclax (ABT199) are BCL2 inhibitors which can be used for the treatment of relapsed/refractory HL and previously untreated FL while in combination with rituximab through restoring normal apoptosis. 58e60 p53 p53, a well-known nuclear transcription factor and tumor suppressor protein, targets a broad spectrum of functional genes regulating physiological cellular functions and mediates cell apoptosis and growth arrest with the interaction with BCL2 family members and other molecules. 61, 62 As a result, p53 inactivation or the dysregulation of p53-involved signaling pathway has been implicated to be oncogenic event for cancers, including lymphomas. 61, 63 Theoretically speaking, it seems rational to restore tumor suppressor function of p53, to interrupt mouse double minute-2 homolog (MDM2)-p53 interaction, and to reactivate p53-mediated apoptosis pathways for the development of therapeutics against p53-related malignancies. For example, as a MDM2 inhibitor, APG-115 is such an agent which showed antitumor activities in multiple human cancer xenograft models. It may be able to show activity and safety in human cancer.
61,64e66
Myc Myc is well known as a representative pleiotropic transcription factor and an oncogene protein, targeting numerous genes and regulating multiple processes of cell biology and oncology. 67, 68 Myc has also been associated with oncogenesis, malignant transformation, and aggressive clinical features in many aggressive cancers including aggressive lymphomas. In BL and a subset of DLBCL, chromosomal translocation of MYC like t(8; 14)(q24; q32) is considered as typical oncogenic event and aggressive feature. MYC translocation accompanied by BCL2 or BCL6 is termed as double-hit or triple-hit lymphoma with relatively unfavorable prognosis. A similar situation also occurs in the double-expression lymphoma with Myc and BCL2 co-overexpression. Therefore, both MYC translocation and Myc overexpression have reference value for diagnosis and prognosis of lymphoma in clinical practice. 67, 69 As for the development of Myc targeting therapeutics, JQ1, a type of small molecule inhibitor against bromodomain-containing protein 4 (BRD4), showed encouraging efficacy in patients with hematologic or some other Myc-driven malignancies through downregulating Myc function and expression. 70, 71 Another Myc inhibitor against bromodomain and extra-terminal domain (BET)/BRD4 is AZD5153, which showed activity for hematologic malignancies by transcriptionally affecting Myc, E2 promoter binding factor (E2F), and mTOR. 72 Other strategies for developing Myctargeted therapeutics may be established in reducing Myc/Myc associated factor X (MAX) heterodimerization and DNA binding, affecting MYCassociated chromatin modification, targeting cell cycle kinases, and interfering with its downstream target genes. 73 
PD-1/PD-Ls signaling pathway
As a pair of co-inhibitory molecules, normal PD-1 and PD-Ls are employed by immune system to balance immune function. Normally, PD-1 negatively regulates effector T-cell functions with the inhibition of T-cell receptor (TCR)/CD3/zeta chain of T cell receptor associated protein kinase 70 (ZAP70) signaling mediated by Src homology region 2 domaincontaining phosphatase-1/2 (SHP-1/2) (Fig. 2) . 74, 75 However, under the triggering of genetic alteration, virus infection, or other conditions in the pathological process, overexpressed PD-Ls in tumor cells and infiltrating cells lead to exhaustion of effector T cell and final immune escape. Such an immune escape signaling pathway contributes to oncogenesis, tumor aggression and metastasis in many types of malignancies. 74, 76 Many other immune checkpoint pathways and molecules involved in lymphoma can also function like PD-1/PD-Ls signaling. Such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-40)/CD86/CD80, B and T lymphocyte attenuator (BTLA)/herpes virus entry mediator (HVEM), lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHCII), and T cell immunoglobulin mucin-3 (TIM-3)/galectin-9, which are paired respectively to form costimulatory signals and co-inhibitory signals, participate in these pathways. 4 Encouragingly, targeting and blocking PD-1/PD-Ls pathway by monoclonal antibodies has been approved to apply in clinical immunotherapy management for cHL, DLBCL, and FL. 4, 74 PD-1 and PD-Ls PD-1, as an inhibitory cell surface receptor, is encoded by PDCD1 at locus 2q37.3 and mainly expressed on the surface of activated T-cells. PD-L1 and PD-L2, encoded by CD274 and PDCD1LG2 are generally expressed on antigen presenting cells, activated dendritic cells and some macrophages, respectively. Under some pathological conditions, like CD274 amplification or translocation at 9p24.1, as well as oncogenic activation of JAK/STAT or AP-1 pathways or viral infection, PD-L1 has been seen to be overexpressed in lymphoma cells and stromal cells, particularly in cHL, primary mediastinal B-cell lymphoma (PMBL), and a small part of ABC-DLBCL and anaplastic lymphoma kinase (ALK)-positive ALCL. 74, 75, 77, 78 In FL and CLL/SLL, PD-1 overexpressed in infiltrating T-cells in follicles of lymph node or tumor cells of CLL cases. 79, 80 Interestingly, both PD-L1 and PD-1 overexpression was observed in virus-associated lymphomas. 78, 81, 82 Importantly, accumulating studies have proved that prediction for patient outcome and treatment response is feasible according to the aberrant expression status of PD-1 and PD-L1. Therefore, detection of PD-1 and PD-L1 immunohistochemically will be useful to guide the selection of lymphoma patients. 79, 83, 84 Additionally, PD-1 combined with other follicular T-helper cell markers like chemokine (C-X-C motif) ligand 13 (CXCL-13) are the robust diagnostic biomarkers for angioimmunoblastic T-cell lymphoma (AITL) diagnosis. 85 More excitingly, monoclonal antibodies targeting PD-1, pidilizumab, nivolumab and pembrolizumab, have been approved to be used in hematologic malignancies, including cHL, PMBL, FL, CLL/SLL, particularly in relapsed/refractory patients or in combination with autologous hematopoietic stem cell transplantation.
86e89 Some inhibitors against PD-L1, durvalumab, atezolizumab, and avelumab, have also been approved by FDA for the treatment of some solid tumors. Many other agents against PD-1 and PD-L1 are also under investigation or clinical evaluation in patients with solid tumor and hematologic malignancies. 
JAK/STAT signaling pathway
JAK/STAT signaling pathway essentially mediates cytokine signaling and growth factor signaling, involving a network of molecules with different functions. Upon cytokine receptors-cytokine binding, JAKs and STATs become active sequentially. After that, phosphorylated STATs are dimerized and thereby transfer to nucleus from cytoplasm, causing transcriptional activation of the target genes and eventually regulating apoptosis, proliferation, angiogenesis, and metastasis, etc. In turn, this pathway is negatively regulated by suppressor of cytokine signaling (SOCS) and cytokine-induced STAT inhibitor (CIS) (Fig. 3) . 92e94 The dysregulation of JAK/STAT pathway can be seen in lymphomas such as PMBL, cHL, and ABC-DLBCL. The oncogenic events may result from loss-of-function of positive regulator JAK2, STAT3, STAT5, and Jumonji domain-containing protein 2C (JMJD2C), as well as negative regulator SOCS1 and protein tyrosine phosphatase non-receptor type 2 (PTPN2). 
JAKs
Four JAKs (JAK1, JAK2, JAK3, and tyrosine kinase 2) generally involve in hematopoiesis, host defense, and immune response. Several abnormalities of JAKs have been identified as specific signatures in lymphomas. Aberrant amplification of JAK2 and JMJD2C with loss of function of SOCS1 and PTPN2 have been shown in cHL and PMBL; JAK3 mutation in NK T-cell lymphoma and adult T-cell leukemia/lymphoma, JAK2/SEC31A fusion involving t(4; 9)(q21; p24) in cHL, and JAK2/PCM1 fusion deriving from t(8; 9)(p22; p24) in T-cell lymphoma, all have been identified. 97e100 Inhibitor against JAK2/Fms-like tyrosine kinase 3 (FLT3) fusion, pacritinib (SB1518), has been developed for treatment of relapsed/refractory cHL, FL, and DLBCL, demonstrating clinical safety and efficacy. 101 Meanwhile, tofacitinib, JAK3 inhibitor, has therapeutic efficacy for EBV-associated NK-and T-cell lymphoma, probably due to its ability to decrease STAT5 phosphorylation, to inhibit proliferation, and to reduce EBV latency. 
STATs
STATs family consist of seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. STAT3 expression increased significantly in ABC-DLBCL and ALCL patients; in the latter, nucleophosmin 1 (NPM-1)/ALK fusion was proposed to be related to increased STAT3. 93, 103, 104 Additionally, STAT3 and STAT5 activation can be observed in cutaneous T-cell lymphoma, and STAT6 mutation occurs in PMBL and FL. 105, 106 Therapeutically, a STAT3 inhibitor, pyrimethamine, for the treatment of relapsed CLL/SLL, is being estimated in phase I/II clinical trial (Clinical Trials Registration: NCT01066663).
Remarks and conclusion
As noted above, it has been well recognized that complicate network of dysregulated signaling pathways and their hidden oncogenic alterations contribute a lot to lymphoma oncogenesis and heterogeneity. In the era of precision medicine, it is imperative to precisely identify the dysregulation of these signaling pathways and the "driver" oncogenic biomarkers; it is meaningful to further understand the underlying mechanisms of the dysregulated signaling pathways and to address the potential utility of pathway-related biomarkers. Table 1 summarized the pathway-related biomarkers and their clinical utilities in lymphoid malignancies.
With the progress of biotechnologies and the application of advanced detection platform, identifying pathway-based biomarkers becomes available, providing good opportunities to utilize these biomarkers reasonably and feasibly. The two most promising utilizations lie in precise diagnosis and treatment. Instead of relying solely on morphologic and histologic features and clinical experience, molecular classification based on specific biomarker has almost become a requirement for diagnosis, risk-stratification, and treatment-guidance in some lymphoid malignancies.
These pathway-based biomarkers may include gene rearrangement, gene amplification, specific tumordriving mutations, epigenetic alterations, unusual expressions, as well as other abnormal genotypes and phenotypes. Therefore, faced with so many complicate alterations, there are big challenges to utilize these biomarkers reasonably and efficiently.
In biomarkers screening and detecting, reliable and reproducible biomarkers accurately conveying activated oncogenic pathways in patients will be needed.
For example, PD-1 and PD-L1 are not only the therapeutically targeted biomarkers but also predictive biomarkers to guide patients who may benefit from immunotherapy. Moreover, PD-1 is useful for AITL diagnosis. In practice, the robustness of PD-1 and PD-L1 detection may depend on the specificity and sensitivity of the antibody, the platform or method used, the status of intra-tumor heterogeneity, and other factors.
Additionally, in front of enormous amount of information triggered by complex techniques, especially by next generation sequencing (NGS), we are confronted with many problems in the discovery and application of new biomarkers. For instance, despite NGS is becoming more and more popular and the cost is getting lower and lower, in clinical practice, a panel sequencing focusing on a limited number of genes is still a better option than whole genome sequencing. Nevertheless, it will be a trend to apply whole genome sequencing and transcriptome sequencing in routine clinical practice in the future with the advances of technology and increased availability. Another focus is that in addition to single specific diagnostic or prognostic biomarker, rational algorithms or some grouped gene signatures are of great value for routine diagnosis, classification, prognosis, prediction, or monitoring in lymphomas. In fact, a lot has been put into practice.
As for precision treatment, many arguments have emerged. Are patients with malignancies matched with drugs for mutations or "pathway" mutations? Why did the current targeted drugs not achieve desired therapeutic effect in clinical practice? How do clinicians choose the best treatment regimens? Single targeted agent alone? Or in combination with multiple pathway inhibitors? We do need to notice and address these issues. It will be difficult to assess the effect of combination regimens using predictive biomarkers from individual patient. Probably a long-time and large population validation is required for the effect of predictive biomarkers and targeted therapies. In addition, the side effects of these targeted therapies in lymphomas are also of great concern. Here, we summarized the side effects of agents targeting pathwayrelated biomarkers in Table 2 .
In conclusion, despite the many problems encountered, pathway-based targeted therapy in combination with traditional chemotherapy, single specific targeted antibody, and immunotherapy will raise the hope for the patients with lymphoid malignancies. The rational and efficient utilization of pathway-related biomarkers in diagnosis, prognosis, prediction, and treatment selection in lymphoid malignancies will power precision medicine. 
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